Entrada Therapeutics (Entrada Therapeutics) Beneish M-Score : 4.15 (As of May. 28, 2024)

View and export this data going back to 2021. Start your Free Trial

What is Entrada Therapeutics Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Warning Sign:

Beneish M-Score 4.15 higher than -1.78, which implies that the company might have manipulated its financial results.

The historical rank and industry rank for Entrada Therapeutics's Beneish M-Score or its related term are showing as below:

TRDA' s Beneish M-Score Range Over the Past 10 Years
Min: 4.15 Med: 4.15 Max: 4.15
Current: 4.15

During the past 5 years, the highest Beneish M-Score of Entrada Therapeutics was 4.15. The lowest was 4.15. And the median was 4.15.

Entrada Therapeutics Beneish M-Score Historical Data

The historical data trend for Entrada Therapeutics's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Entrada Therapeutics Beneish M-Score Chart

Entrada Therapeutics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Beneish M-Score

Entrada Therapeutics Quarterly Data
	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Beneish M-Score	Get a 7-Day Free Trial												-	-	-	-	4.15

Competitive Comparison of Entrada Therapeutics's Beneish M-Score

For the Biotechnology subindustry, Entrada Therapeutics's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Entrada Therapeutics's Beneish M-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Entrada Therapeutics's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Entrada Therapeutics's Beneish M-Score falls into.

Entrada Therapeutics Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Entrada Therapeutics for today is based on a combination of the following eight different indices:

-4.84

0.92 * DSRI

0.528 * GMI

0.404 * AQI

0.892 * SGI

0.115 * DEPI

-4.84

0.92 * 1.9091

0.528 * 1

0.404 * 0.3512

0.892 * 6.4479

0.115 * 2.2953

0.172 * SGAI

4.679 * TATA

0.327 * LVGI

0.172 * 0.1628

4.679 * 0.22042

0.327 * 1.3786

4.15

This Year (Mar24) TTM:

Last Year (Mar23) TTM:

Total Receivables was $77.5 Mil.
Revenue was 59.12 + 41.848 + 43.735 + 18.17 = $162.9 Mil.
Gross Profit was 59.12 + 41.848 + 43.735 + 18.17 = $162.9 Mil.
Total Current Assets was $414.2 Mil.
Total Assets was $510.8 Mil.
Property, Plant and Equipment(Net PPE) was $90.0 Mil.
Depreciation, Depletion and Amortization(DDA) was $3.2 Mil.
Selling, General, & Admin. Expense(SGA) was $33.8 Mil.
Total Current Liabilities was $173.9 Mil.
Long-Term Debt & Capital Lease Obligation was $58.1 Mil.
Net Income was 23.496 + -9.544 + 35.461 + -25.928 = $23.5 Mil.
Non Operating Income was 0 + 0 + 0 + 0 = $0.0 Mil.
Cash Flow from Operations was -25.519 + -4.013 + -24.492 + -35.091 = $-89.1 Mil.

Total Receivables was $6.3 Mil.
Revenue was 25.26 + 0 + 0 + 0 = $25.3 Mil.
Gross Profit was 25.26 + 0 + 0 + 0 = $25.3 Mil.
Total Current Assets was $434.1 Mil.
Total Assets was $475.6 Mil.
Property, Plant and Equipment(Net PPE) was $23.6 Mil.
Depreciation, Depletion and Amortization(DDA) was $2.0 Mil.
Selling, General, & Admin. Expense(SGA) was $32.1 Mil.
Total Current Liabilities was $147.6 Mil.
Long-Term Debt & Capital Lease Obligation was $9.1 Mil.

1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI	=	(Receivables_t / Revenue_t)	/	(Receivables_t-1 / Revenue_t-1)
	=	(77.514 / 162.873)	/	(6.297 / 25.26)
	=	0.475917	/	0.249287
	=	1.9091

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI	=	GrossMargin_t-1	/	GrossMargin_t
	=	(GrossProfit_t-1 / Revenue_t-1)	/	(GrossProfit_t / Revenue_t)
	=	(25.26 / 25.26)	/	(162.873 / 162.873)
	=	1	/	1
	=	1

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI	=	(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t)	/	(1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
	=	(1 - (414.172 + 89.96) / 510.844)	/	(1 - (434.135 + 23.641) / 475.569)
	=	0.013139	/	0.037414
	=	0.3512

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI	=	Sales_t	/	Sales_t-1
	=	Revenue_t	/	Revenue_t-1
	=	162.873	/	25.26
	=	6.4479

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI	=	(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1))	/	(Depreciation_t / (Depreciaton_t + PPE_t))
	=	(2.046 / (2.046 + 23.641))	/	(3.234 / (3.234 + 89.96))
	=	0.079651	/	0.034702
	=	2.2953

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI	=	(SGA_t / Sales_t)	/	(SGA_t-1 /Sales_t-1)
	=	(33.752 / 162.873)	/	(32.144 / 25.26)
	=	0.207229	/	1.272526
	=	0.1628

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI	=	((LTD_t + CurrentLiabilities_t) / TotalAssets_t)	/	((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
	=	((58.131 + 173.938) / 510.844)	/	((9.122 + 147.594) / 475.569)
	=	0.454285	/	0.329534
	=	1.3786

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA	=	(IncomefromContinuingOperations_t	-	CashFlowsfromOperations_t)	/	TotalAssets_t
	=	(NetIncome_t - NonOperatingIncome_t	-	CashFlowsfromOperations_t)	/	TotalAssets_t
	=	(23.485 - 0	-	-89.115)	/	510.844
	=	0.22042

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Entrada Therapeutics has a M-score of 4.15 signals that the company is likely to be a manipulator.

Entrada Therapeutics Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Entrada Therapeutics's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.

Entrada Therapeutics (Entrada Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Entrada Therapeutics Inc (NAS:TRDA) » Definitions » Beneish M-Score

Comparable Companies

Traded in Other Exchanges

N/A

Address

6 Tide Street, Boston, MA, USA, 02210

Website

https://www.entradatx.com

Entrada Therapeutics Inc mission is to transform the treatment of devastating diseases and improve patients quality of life by developing intracellular biologics. Leveraging its proprietary Endosomal Escape Vehicle platform, Entrada is creating a diverse and expanding pipeline of oligonucleotide, antibody, enzyme, protein and peptide programs to efficiently target and engage underlying drivers of diseases.

Executives

Dipal Doshi	director, officer: President and CEO	C/O AMICUS THERAPEUTICS, 1 CEDAR BROOK DRIVE, CRANBURY NJ 08512
Kory James Wentworth	officer: Chief Financial Officer	6 TIDE STREET, C/O ENTRADA THERAPEUTICS, BOSTON MA 02210
Nathan J Dowden	officer: Chief Operating Officer	6 TIDE STREET, BOSTON MA 02210
Nerissa Kreher	officer: Chief Medical Officer	C/O AVROBIO, INC., ONE KENDALL SQ., BLDG. 300, STE. 201, CAMBRIDGE MA 02139
Gina Chapman	director	C/O CARGO THERAPEUTICS, INC., 1900 ALAMEDA DE LAS PULGAS, SUITE 350, SAN MATEO CA 94403
Natarajan Sethuraman	officer: Chief Scientific Officer	6 TIDE STREET, BOSTON MA 02210
Bernhardt G Zeiher	director	ENTRADA THERAPEUTICS, INC., 6 TIDE STREET, BOSTON MA 02210
Baker Bros. Advisors Lp	10 percent owner	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Todd Foley	director, 10 percent owner	THE JOHN HANCOCK TOWER, 200 CLARENDON STREET 54TH FLOOR, BOSTON MA 02116
Felix Baker	10 percent owner	BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014
Julian Baker	10 percent owner	BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014
Baker Bros. Advisors (gp) Llc	10 percent owner	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
John F Crowley	director	C/O AMICUS THERAPEUTICS, INC., 1 CEDAR BROOK DRIVE, CRANBURY NJ 08512
Redmile Group, Llc	10 percent owner	ONE LETTERMAN DRIVE, BUILDING D, SUITE D3-300, SAN FRANCISCO CA 94129
Mpm Bioventures 2018, L.p.	10 percent owner	450 KENDALL STREET, CAMBRIDGE MA 02142